MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.
Key Details
- 1Path-IO uses routine pathological slides to identify features predicting immunotherapy response in NSCLC patients.
- 2In validation on over 1,000 patients across multiple institutions and countries, Path-IO significantly outperformed PD-L1 testing, the current standard biomarker.
- 3The AI model stratified patients into high- and low-risk groups, with high-risk patients experiencing double the probability of death or progression.
- 4Unlike 'black box' models, Path-IO leverages established tissue features for explainable, clinically translatable decision-making.
- 5Researchers are integrating radiomics and clinical data to further improve Path-IO's prediction accuracy and plan to include CT, genomics, and other multimodal data in the future.
- 6Prospective clinical validation is the next planned step, and the model may evolve into a digital twin framework for comprehensive clinical decision support.
Why It Matters
Path-IO's superior accuracy and explainability provide a pathway for more personalized and effective treatment decisions in oncology. The integration with radiomics and clinical imaging data signals a promising future for multimodal AI in precision medicine, especially for radiology and pathology collaborations.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.